The Institute of Cancer Research attracts the very best science graduates and clinicians to carry out cutting-edge research and make the discoveries that defeat cancer. Our students enjoy working in a high-tech and collaborative environment, in which their research can be translated into direct benefits for patients.
I am a second year PhD student in the Radiotherapy and Imaging Division at the ICR and the Mechanical Engineering department at Imperial College London. My joint PhD is part of the new Convergence Science Centre at the ICR and Imperial – bringing together researchers working across physics, data science, engineering, the biological sciences and medicine to tackle questions in cancer.
Nithya Paranthaman is a second-year PhD student in our Division of Molecular Pathology. She is developing and optimising micro-sampling techniques to monitor multiple myeloma – specifically a blood-sampling tool that patients can perform from the comfort of their own home.
Irene Matucci is carrying out a PhD in the Molecular Addictions Team, studying the interplay between metabolism and cancer cell signalling with a focus on glioblastoma, intestinal and breast cancer. She is the President of the ICR’s Student Union.
Joshua Freedman is a third-year PhD student in the Division of Radiotherapy and Imaging. His research is helping to develop the MR Linac, a revolutionary new type of radiotherapy machine which is currently being tested for the first time on patients.
Laura is a Cancer Research UK-funded PhD student in the Division of Structural Biology, working to understand how deregulation of a protein known as RNA polymerase III can cause cancer.
Daniel Lam’s PhD project in the Therapeutic Ultrasound team is working towards the development of a new software programme which will help clinicians to determine, from a standard referral image, whether a patient is treatable with ultrasound.
Stephen Turnock is doing his PhD in the Preclinical Molecular Imaging team, looking at imaging biomarkers that can be used for monitoring treatment response in neuroblastoma.
Somaieh Hedayat is working towards a PhD on how the tissue microenvironment can affect the response of metastatic colorectal cancer cells to antiangiogenic therapies.
Oliver Pickford Scienti is doing a PhD in the Multimodal Molecular Imaging Team which involves using gold nanoparticles to help improve the effectiveness of radiotherapy.
David McBay's PhD project aims to understand the molecular mechanisms that determine the effectiveness of fractionated radiotherapy.
Applications for our main PhD recruitment round have opened. We’re searching for the brightest minds in cancer research. The deadline for applications is 17 November.